Repligen Corporation (NASDAQ:RGEN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Repligen Corporation (NASDAQ:RGEN) have received an average recommendation of “Moderate Buy” from the fourteen brokerages that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $176.9167.

A number of equities research analysts recently weighed in on RGEN shares. Wells Fargo & Company lowered their target price on shares of Repligen from $190.00 to $180.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. KeyCorp reiterated an “overweight” rating on shares of Repligen in a research note on Wednesday, February 25th. Wall Street Zen lowered shares of Repligen from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. UBS Group decreased their price objective on shares of Repligen from $200.00 to $195.00 and set a “buy” rating for the company in a research note on Wednesday, February 25th. Finally, HC Wainwright increased their price objective on shares of Repligen from $180.00 to $208.00 and gave the company a “buy” rating in a research note on Monday, March 23rd.

Repligen Trading Down 0.7%

RGEN opened at $116.95 on Tuesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.37 and a quick ratio of 7.12. Repligen has a fifty-two week low of $102.96 and a fifty-two week high of $175.77. The firm has a market capitalization of $6.59 billion, a PE ratio of 137.59, a P/E/G ratio of 2.30 and a beta of 1.19. The company’s 50-day moving average is $129.44 and its 200 day moving average is $146.60.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. Repligen had a net margin of 6.62% and a return on equity of 4.71%. The company had revenue of $197.91 million for the quarter, compared to analyst estimates of $192.23 million. During the same quarter in the prior year, the business posted $0.44 EPS. The firm’s revenue was up 18.1% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. As a group, research analysts predict that Repligen will post 1.72 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Repligen

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Measured Wealth Private Client Group LLC purchased a new stake in Repligen in the 3rd quarter valued at about $29,000. Bayforest Capital Ltd purchased a new stake in Repligen in the 4th quarter valued at about $32,000. Rachor Investment Advisory Services LLC purchased a new stake in Repligen in the 4th quarter valued at about $33,000. Los Angeles Capital Management LLC purchased a new stake in Repligen in the 4th quarter valued at about $36,000. Finally, CWM LLC increased its stake in Repligen by 67.2% in the 3rd quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 135 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.